(Q53791009)

19 May 2018

editorial

0 references

title

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. (English)

1 reference

19 May 2018

1 reference

5

Bradley J Monk

1 reference

19 May 2018

Ursula A. Matulonis

2

object named as

Ursula A Matulonis

1 reference

19 May 2018

author name string

Ronald D Alvarez

1

1 reference

19 May 2018

Thomas J Herzog

3

1 reference

19 May 2018

Robert L Coleman

4

1 reference

19 May 2018

Maurie Markman

6

1 reference

19 May 2018

language of work or name

English

0 references

publication date

8 April 2016

1 reference

19 May 2018

published in

Gynecologic Oncology

1 reference

19 May 2018

volume

141

1 reference

19 May 2018

issue

3

1 reference

19 May 2018

page(s)

405-409

1 reference

19 May 2018

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Ovarian cancer, version 2.2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Clinical Utility of Positron Emission Tomography/Computed Tomography in the Evaluation of Suspected Recurrent Ovarian Cancer in the Setting of Normal CA-125 Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.005

10.1016/J.YGYNO.2016.03.005

7 January 2021

Identifiers

DOI

1 reference

19 May 2018

1 reference

19 May 2018